GMDx was the first to use genomic data to identify Cancer Progression Associated Signatures (CPAS)* and we have developed proprietary methods to predict cancer progression for a range of cancers.
GMDx-CPAS has now verified on several cancer types. More than 10,000 patient genomes across 33 tumour types were analysed. GMDx IIF profiles were generated for all patients in this cohort that had “Progression Free Survival” (PFS) recorded (n=9,433) and a verifiable method for CPAS was developed to predict cancer progression. Accuracy, sensitivity and specificity was very high and, in some cases it was 100%.